BioTuesdays

Tag - Kristen Kluska

Hepion Pharmaceuticals
Markets

Cantor starts Hepion Pharma at OW; PT $3.50

Cantor Fitzgerald launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with an “overweight” rating and $3.50 price target. The stock closed at $1.03 on Feb. 25. Hepion’s lead asset, Rencofilstat (CRV431)...

February 28, 2022
Markets

Cantor starts Evelo Biosciences at OW; PT $28

Cantor Fitzgerald launched coverage of Evelo Biosciences (NASDAQ:EVLO) with an “overweight” rating and 12-month price target of $28. The stock closed at $16.08 on June 22. Evelo is developing oral therapies derived from...

June 23, 2021
Chemomab-Therapeutics
Markets

Cantor starts Chemomab Therapeutics at OW; PT $45

Cantor Fitzgerald initiated coverage of Chemomab Therapeutics (NASDAQ:CMMB) with an “overweight” rating and $45 price target. The stock closed at $16.07 on May 25. Chemomab is a clinical-stage biotech company focusing...

May 26, 2021
Lineage-Cell-Therapeutics-Logo
Markets

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...

March 31, 2021
Heat Biologics
Markets

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

March 3, 2021
iBio Inc. Logo
Markets

Cantor Fitzgerald starts iBio at OW; PT $3

Cantor Fitzgerald launched coverage of iBio (NYSE American:IBIO) with an “overweight” rating and price target of $3. The stock closed at $1.46 on Jan. 21. iBio focuses on plant-made biologics manufacturing, which is...

January 22, 2021